Cabozantinib in genitourinary malignancies. - Test2 - elhamkhani - TriplyDB

Cabozantinib in genitourinary malignancies.

Cabozantinib in genitourinary malignancies.

http://www.wikidata.org/entity/Q38795560

about

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

P2860

Q46493299-009343F4-FB7E-445C-AA22-CE03D66C44DB

P2860

Cabozantinib in genitourinary malignancies.

http://www.wikidata.org/entity/Q38795560

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cabozantinib in genitourinary malignancies.

@en

type

label

Cabozantinib in genitourinary malignancies.

@en

prefLabel

Cabozantinib in genitourinary malignancies.

@en

P1433

Q38795560-4ED637DB-F906-43D3-9064-8494B8289987

P1476

Q38795560-0AEC036C-A2B3-46E5-91E0-E394575D2F51

P2093

Q38795560-14663349-7C9E-426F-A68F-2240BF948A92

Q38795560-35E588E3-EAA6-4C9B-9972-90C687D85AD3

Q38795560-85361030-CACB-4158-AB8A-2E33F2FF259C

Q38795560-9E934B2B-3F36-4C91-B6A3-DA5ED83563A7

P2860

Q38795560-050D8954-0200-4FCE-852D-E7C29EF02E5C

Q38795560-0530009E-317E-4FB2-A71D-BCF24AAD6040

Q38795560-06DCECF1-2317-44FA-9CBE-438481EB82DE

Q38795560-08FED25A-56AD-490C-9FBE-8A1DF6A1BE86

Q38795560-0E12E7EC-25F6-46F4-B680-3CC1CC281D26

Q38795560-204E5AEF-0FD2-45CA-88F6-2381E37108C4

Q38795560-22B30D71-341E-414B-B78E-EC06DABCAE60

Q38795560-283A0D55-1B7B-48DA-920A-7D7422AB6829

Q38795560-29237B95-D40A-49C9-8CBC-640562AB3A1C

Q38795560-351325C7-5433-4529-84DF-60A63D37258F

P304

Q38795560-9A6B2DF8-5F71-4D18-AB3E-0BFD2097B9D7

P31

Q38795560-471C6AC8-4322-4D75-8001-14EC172C38FD

P356

Q38795560-BCB436C7-87DF-4917-A3C4-30D886C00081

P407

Q38795560-001C2B46-7CD2-461C-980A-5554E91F7B13

P433

Q38795560-D45C22F1-CB7A-4326-BD14-43522C320CE5

P478

Q38795560-142200CC-5708-4104-824D-0A20D105A5B3

P577

Q38795560-B6A91B62-3C0C-4AF3-8976-2A7325AA58B3

P698

Q38795560-74E5215B-DD44-42D8-9DA0-55408E2CF6C1

P356

P1433

Future Oncology

P1476

Cabozantinib in genitourinary malignancies.

@en

P2093

Cierra Hong

http://www.w3.org/2001/XMLSchema#string

Daniel J George

http://www.w3.org/2001/XMLSchema#string

Se Eun Park

http://www.w3.org/2001/XMLSchema#string

Tian Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Cancer statistics, 2015

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

Cancer statistics, 2016

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Cabozantinib in progressive medullary thyroid cancer.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

P304

755-765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0358

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27842445

http://www.w3.org/2001/XMLSchema#string